| Document and Entity Information - shares | 3 Months Ended | |
| Mar. 31, 2017 | Apr. 30, 2017 | |
| Document and Entity Information [Abstract] | ||
| Entity Registrant Name | OptimizeRx Corp | |
| Entity Central Index Key | 1,448,431 | |
| Trading Symbol | OPRX | |
| Amendment Flag | false | |
| Current Fiscal Year End Date | --12-31 | |
| Document Type | 10-Q | |
| Document Period End Date | Mar. 31, 2017 | |
| Document Fiscal Year Focus | 2,017 | |
| Document Fiscal Period Focus | Q1 | |
| Entity Filer Category | Smaller Reporting Company | |
| Entity Common Stock, Shares Outstanding | 29,737,617 |
| Condensed Consolidated Balance Sheets (Unaudited) - USD ($) | Mar. 31, 2017 | Dec. 31, 2016 |
| Current Assets | ||
| Cash and cash equivalents | $ 6,721,265 | $ 7,034,647 |
| Accounts receivable | 2,807,322 | 3,060,396 |
| Prepaid expenses | 62,081 | 80,820 |
| Total Current Assets | 9,590,668 | 10,175,863 |
| Property and equipment, net | 182,295 | 173,649 |
| Other Assets | ||
| Patent rights, net | 755,422 | 772,394 |
| Web development costs, net | 391,803 | 351,804 |
| Security deposit | 5,049 | 5,049 |
| Total Other Assets | 1,152,274 | 1,129,247 |
| TOTAL ASSETS | 10,925,237 | 11,478,759 |
| Current Liabilities | ||
| Accounts payable - trade | 530,442 | 369,214 |
| Accrued expenses | 57,293 | 288,268 |
| Revenue share payable | 1,948,787 | 2,622,517 |
| Deferred revenue | 1,329,774 | 386,581 |
| Total Liabilities | 3,866,296 | 3,666,580 |
| Stockholders' Equity | ||
| Common stock, $.001 par value, 500,000,000 shares authorized, 29,737,617 and 29,718,867 shares issued and outstanding, respectively | 29,738 | 29,719 |
| Preferred stock, $.001 par value, 10,000,000 shares authorized, 0 and 65 shares issued and outstanding, respectively | ||
| Stock warrants | 2,294,416 | 2,294,416 |
| Additional paid-in-capital | 33,876,562 | 33,747,137 |
| Accumulated deficit | (29,141,775) | (28,259,093) |
| Total Stockholders' Equity | 7,058,941 | 7,812,179 |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ 10,925,237 | $ 11,478,759 |
| Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares | Mar. 31, 2017 | Dec. 31, 2016 |
| Statement of Financial Position [Abstract] | ||
| Common stock, par value | $ 0.001 | $ 0.001 |
| Common stock, shares authorized | 500,000,000 | 500,000,000 |
| Common stock, shares issued | 29,737,617 | 29,718,867 |
| Common stock, shares outstanding | 29,737,617 | 29,718,867 |
| Preferred Stock, par value | $ 0.001 | $ 0.001 |
| Preferred stock, shares authorized | 10,000,000 | 10,000,000 |
| Preferred stock, shares issued | 0 | 65 |
| Preferred stock, shares outstanding | 0 | 65 |
| Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
| Mar. 31, 2017 | Mar. 31, 2016 | |
| Income Statement [Abstract] | ||
| NET REVENUE | $ 2,152,073 | $ 1,759,528 |
| COST OF SALES | 1,381,733 | 892,793 |
| GROSS MARGIN | 770,340 | 866,735 |
| OPERATING EXPENSES | 1,660,778 | 1,228,564 |
| LOSS FROM OPERATIONS | (890,438) | (361,829) |
| OTHER INCOME (EXPENSE) | ||
| Interest income | 7,756 | 10,076 |
| Interest Expense | (163) | |
| TOTAL OTHER INCOME (EXPENSE) | 7,756 | 9,913 |
| LOSS BEFORE PROVISION FOR INCOME TAXES | (882,682) | (351,916) |
| PROVISION FOR INCOME TAXES | ||
| NET LOSS | $ (882,682) | $ (351,916) |
| WEIGHTED AVERAGE SHARES OUTSTANDING | ||
| BASIC AND DILUTED | 29,718,867 | 29,030,925 |
| NET LOSS PER SHARE | ||
| BASIC AND DILUTED | $ (0.03) | $ (0.01) |
| Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | |
| Mar. 31, 2017 | Mar. 31, 2016 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss for the period | $ (882,682) | $ (351,916) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||
| Depreciation and amortization | 84,473 | 50,268 |
| Stock and options issued for services | 129,444 | 106,384 |
| Changes in: | ||
| Accounts receivable | 253,074 | 506,685 |
| Prepaid expenses | 18,739 | 16,068 |
| Accounts payable | 161,228 | (380,115) |
| Revenue share payable | (673,730) | (852,792) |
| Accrued expenses | (230,975) | 1,107 |
| Deferred revenue | 943,193 | 618,224 |
| NET CASH (USED IN) OPERATING ACTIVITIES | (197,236) | (286,087) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Patent rights | (1,295) | |
| Equipment | (16,146) | (14,507) |
| Development and integration costs | (100,000) | |
| NET CASH USED IN INVESTING ACTIVITIES | (116,146) | (15,802) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Repurchase of common stock payable | (357,415) | |
| NET CASH USED IN FINANCING ACTIVITIES | (357,415) | |
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | (313,382) | (659,304) |
| CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD | 7,034,647 | 8,207,565 |
| CASH AND CASH EQUIVALENTS - END OF PERIOD | 6,721,265 | 7,548,261 |
| SUPPLEMENTAL CASH FLOW INFORMATION: | ||
| Cash paid for interest | 163 | |
| Cash paid for income taxes | ||
| Nature of Business and Basis of Presentation | 3 Months Ended |
| Mar. 31, 2017 | |
| Nature of Business and Basis of Presentation [Abstract] | |
| NATURE OF BUSINESS AND BASIS OF PRESENTATION | NOTE 1 – NATURE OF BUSINESS AND BASIS OF PRESENTATION We are a leading digital health aggregator of pharmaceutical sponsored services in the Electronic Health Records (EHR) space. Our objective is to leverage our proprietary technology to provide on demand savings and clinical messaging within physician and patient web based platforms, including EHR, e-prescribing platforms, pharmacies and Patient Portals. We have matured as a technology solutions provider through our direct to physician solutions, which allow physicians to automatically display and distribute sample vouchers and/or co-pay coupons electronically within the ePrescription platform to pharmacies on behalf of their patients. The OptimizeRx solution is integrated into the ePrescribing or EHR applications, but can also be accessed on a mobile device as well as an application on a prescriber’s desktop. The consolidated financial statements for the three months ended March 31, 2017 and 2016 have been prepared by us without audit pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. In the opinion of management, all adjustments necessary to present fairly our financial position, results of operations, and cash flows as of March 31, 2017 and 2016, and for the periods then ended, have been made. Those adjustments consist of normal and recurring adjustments. The consolidated balance sheet as of December 31, 2016, has been derived from the audited consolidated balance sheet as of that date. Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, as filed with the U.S. Securities and Exchange Commission. The results of operations for the three-months ended March 31, 2017, are not necessarily indicative of the results to be expected for the full year. Certain reclassifications have been made in the prior period’s consolidated financial statements to conform to the current period’s presentation. |
| Stockholders' Equity | 3 Months Ended |
| Mar. 31, 2017 | |
| Stockholders' Equity [Abstract] | |
| STOCKHOLDERS' EQUITY | NOTE 2 – STOCKHOLDERS’ EQUITY In March 2017, we issued 18,750 shares of common stock to our independent directors in connection with our Director Compensation Plan, which calls for issuance of 6,250 shares per quarter to each independent director. These shares were valued at $15,375. In March 2016, we issued 12,500 shares of common stock to our independent directors in connection with our Director Compensation Plan, which calls for issuance of 6,250 shares per quarter to each independent director. These shares were valued at $13,125. As described in greater detail in Note 4, related party transactions, in February 2016, we made a one-time payment of $720,415 to our previous CEO in lieu of issuing shares owed to him from prior years. |
| Share Based Payments - Options | 3 Months Ended |
| Mar. 31, 2017 | |
| Share Based Payments - Options [Abstract] | |
| SHARE BASED PAYMENTS - OPTIONS | NOTE 3 – SHARE BASED PAYMENTS – OPTIONS We use the fair value method to account for stock based compensation. We recorded $114,069 and $79,459 in compensation expense in the three-month periods ended March 31, 2017 and 2016, respectively, related to options issued under our stock-based incentive compensation plan. This includes expense related to options issued in prior years for which the requisite service period for those options includes the current year as well as options issued in the current year. The fair value of these instruments was calculated using the Black-Scholes option pricing model. Information related to the assumptions used in this model is set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016. |
| Related Party Transactions | 3 Months Ended |
| Mar. 31, 2017 | |
| Related Party Transactions [Abstract] | |
| RELATED PARTY TRANSACTIONS | NOTE 4 – RELATED PARTY TRANSACTIONS In February 2016, after hiring a new CEO, we paid our previous CEO $720,415 in lieu of issuing him 595,384 shares of common stock owed to him. The amount paid was based on the 50-day average price of $1.21 per share. A total of 295,384 of these shares were due as a result of previously granted stock awards in 2014 and 2015, for which shares had not yet been issued. These shares were recorded as stock payable on the balance sheet at December 31, 2015. The remaining 300,000 shares were due in connection with the purchase of a patent from the previous CEO in 2010. These shares were recorded as accounts payable – related party on the balance sheet at December 31, 2015. The difference between the value the shares were initially recorded at in 2010 and the amount they were redeemed at in 2016 was recorded as additional paid in capital. |
| Contingencies | 3 Months Ended |
| Mar. 31, 2017 | |
| Contingencies [Abstract] | |
| CONTINGENCIES | NOTE 5 – CONTINGENCIES Litigation The company is currently involved in the following legal proceedings. In March 2015, we initiated litigation in federal court against LDM Group, LLC and PDR Network, LLC. That action was dismissed and later re-initiated in Missouri state court. Our claims are related to the breach by LDM of the settlement agreement signed February 28, 2014 to resolve previous litigation with LDM. Following execution of that agreement, LDM failed to live up to its obligations under that settlement agreement including, but not limited to, not allowing us to distribute our eCoupon programs in the LDM network, not allowing us to distribute the LDM patient education programs, and not providing other information on a timely basis or at all as required under the settlement agreement. In addition, our claims include PDR’s breach of the Master Services Agreement requiring PDR’s exclusive use of our eCoupon solution. We assert that PDR’s acquisition of LDM and the use of the LDM network to distribute coupons by PDR violates the agreement between the parties. We are also claiming that LDM and PDR entered a civil conspiracy to violate their respective agreements with us. We are seeking enforcement of the agreements and we are seeking damages in an amount at least equal to the amounts paid to date to LDM under the settlement agreement, which is in excess of $1.0 million, as well as damages for lost income and business value. The parties are currently in the discovery process. |
| Subsequent Events | 3 Months Ended |
| Mar. 31, 2017 | |
| Subsequent Events [Abstract] | |
| SUBSEQUENT EVENTS | NOTE 6 – SUBSEQUENT EVENTS In accordance with ASC 855-10, we have analyzed our operations subsequent to March 31, 2017 through the date these financial statements were issued and have determined that we do not have any material subsequent events to disclose in these financial statements. |
| Stockholders' Equity (Details) - USD ($) | 1 Months Ended | 3 Months Ended | |
| Feb. 29, 2016 | Mar. 31, 2017 | Mar. 31, 2016 | |
| Director [Member] | |||
| Stockholders' Equity (Textual) | |||
| Shares of common stock | 18,750 | 12,500 | |
| Additional shares issued | 6,250 | 6,250 | |
| Additional shares issued, value | $ 15,375 | $ 13,125 | |
| CEO [Member] | |||
| Stockholders' Equity (Textual) | |||
| Related party transactions | $ 720,415 | ||
| Share Based Payments - Options (Details) - USD ($) | 3 Months Ended | |
| Mar. 31, 2017 | Mar. 31, 2016 | |
| Share Based Payments - Options (Textual) | ||
| Compensation expense | $ 114,069 | $ 79,459 |
| Related Party Transactions (Details) - USD ($) | 1 Months Ended | 12 Months Ended | ||
| Feb. 29, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2010 | |
| Related Party Transactions (Textual) | ||||
| Total common granted stock | 295,384 | 295,384 | ||
| CEO [Member] | ||||
| Related Party Transactions (Textual) | ||||
| Related party transactions | $ 720,415 | |||
| Shares of common stock issued | 595,384 | |||
| Average price per share | $ 1.21 | |||
| Shares issued for in connection with purchase of a patent | 300,000 | |||
| Contingencies (Details) $ in Millions | Mar. 31, 2015USD ($) |
| LDM Group [Member] | |
| Contingencies (Textual) | |
| Damage related to LDM' s breach of the agreement | $ 1 |
| PDR Network [Member] | |
| Contingencies (Textual) | |
| Damage related to LDM' s breach of the agreement | $ 1 |
